SoftBank has contributed to a $350m private placement supporting the health screening provider's reverse takeover.
US-based health information provider Sema4 has completed a reverse merger with special purpose acquisition company CM Life Sciences backed by financing from investors including telecommunications and internet group SoftBank.
The combined business is now trading its common stock and warrants on the Nasdaq Global Select Market under the ticker symbols SMFR and SMFRW respectively. CM Life Sciences floated on the Nasdaq Capital Market in a $385m initial public offering in September 2020.
SoftBank’s SB Management were among the investors…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
